Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD) from Numab Therapeutics in an all-cash deal valued at $1.25 billion.

Anglo-US biotech NodThera has named former Jazz Pharma executive Dan Swisher as its new chief executive, replacing Alan Watt, ...

Asahi Kasei has offered to buy Sweden’s Calliditas Therapeutics for SEK 11.8 billion ($1.1 billion) as part of a plan to ...

The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the ...

Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma ...

Spectrum.Life has followed its recent rebrand with a €17 million ($18.5 million) financing that will be used to expand the ...

AZ’s head of oncology R&D Susan Galbraith pointed out that Dato-DXd is the only investigational therapy to show a “clinically ...

Fuelled by new data showing GLP-1 agonists can have benefits beyond diabetes and obesity – including reducing risk in cardiovascular and kidney disease – the category has been predicted to reach a ...

In fact, it has taken Zarxio five years to achieve a 32 percent market share within the Filgrastim market. 3 In order to increase interest across products, we must create a level playing field for ...

Volta Medical announces positive results from transatlantic TAILORED-AF trial on guided AI procedure During the week of 20th ...

Health technology assessment (HTA) agency NICE has worked with NHS England and other stakeholders, including the MHRA ...

Major pharma companies use an extensive array of legal manoeuvres to keep competition at bay for years, if not decades, after ...